Abstract
HBI-8000 also known as tucidinostat is an orally bioavailable, low-nanomolar inhibitor of cancer-associated histone deacetylase enzymes. HBI-8000 is a histone deacetylase inhibitor (HDACi), and as an epigenetic regulator modulating the gene expression, without changing the DNA sequence. HBI-8000 is being developed as a monotherapy for the treatment of hematological malignancies and in combinations for the treatment of solid tumors such as melanoma, breast, kidney, and lung cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have